Roivant Sciences (ROIV) Price & Analysis

Compare

678 Followers

ROIV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.73 - $16.79

Previous CloseN/A

Volume1.46M

Average Volume (3M)8.58M

Market Cap

$11.10B

Enterprise Value$3.73B

Total Cash (Recent Filing)$4.50B

Total Debt (Recent Filing)$99.69M

Price to Earnings (P/E)1.9

Beta0.99

Next Earnings

Nov 17, 2025

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding682,881,700

10 Day Avg. Volume7,900,684

30 Day Avg. Volume8,577,208

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.34

Enterprise Value/Revenue160.61

Enterprise Value/Gross Profit177.70

Enterprise Value/Ebitda-3.80

Forecast

1Y Price Target

$20.31

Price Target Upside24.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe robust Phase 3 VALOR data of brepocitinib in dermatomyositis shows fast and durable improvement across broad disease symptoms, enhancing its appeal.

Earnings PotentialBrepocitinib is expected to become the first targeted therapy for dermatomyositis by 2027, with anticipated peak sales of ~$1B, raising the price target to $20/share.

Market PositionBrepocitinib's oral therapy and first-mover advantage, especially considering the robustness of results, position it favorably in the market.

Bears Say

Efficacy ConcernsThe primary efficacy of brepocitinib came in modestly below pipeline competitors.

Safety WarningsRoivant expects brepo to carry class-related label safety warning.

Roivant Sciences News

Roivant Sciences files automatic mixed securities shelf

16:33 EDT Roivant Sciences (ROIV) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

5d ago

ROIV

3 Best Stocks to Buy Now, 9/19/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

19d ago

IVA

NVDA

Roivant Sciences price target raised to $16.50 from $12 at BofA

BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $16.50 from $12 and...

20d ago

ROIV

TD Cowen initiates $23 price target for Roivant Sciences

TD Cowen initiated a $24 price target for Roivant Sciences (ROIV) following the release of its announcement that...

20d ago

ROIV

Roivant Sciences price target raised to $20 from $18 at Jefferies

Jefferies raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $18 and keeps a Buy...

20d ago

MRNA

ROIV

Roivant Sciences price target raised to $21 from $15 at Guggenheim

Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $21 from $15 and keeps a Buy...

20d ago

ROIV

Roivant Sciences price target raised to $20 from $16 at JPMorgan

JPMorgan raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $16 and keeps an Overweight...

20d ago

ROIV

Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $18 and keeps a...

20d ago

ROIV

Roivant Sciences rises 11.2%

Roivant Sciences (ROIV) is up 11.2%, or $1.59 to $15.77. Published first on TheFly – the ultimate source...

21d ago

ROIV

General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz

The major averages were mixed near noon ahead of the Federal Reserve’s meeting later in the day. The...

21d ago

Roivant Sciences rises 12.0%

Roivant Sciences (ROIV) is up 12.0%, or $1.70 to $15.88. Published first on TheFly – the ultimate source...

21d ago

ROIV

Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges

Analyst Chi Meng Fong of Bank of America Securities maintained a Hold rating on Roivant Sciences, retaining the...

13d ago

ROIV

Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis

TD Cowen analyst Yaron Werber has maintained their bullish stance on ROIV stock, giving a Buy rating today....

20d ago

ROIV

Roivant Sciences Announces Positive Phase 3 Study Results

Roivant Sciences ( ($ROIV) ) has provided an update. On September 17, 2025, Roivant Sciences announced positive results...

21d ago

ROIV

ROIV FAQ

What was Roivant Sciences Ltd.’s price range in the past 12 months?

Roivant Sciences Ltd. lowest stock price was $8.73 and its highest was $16.79 in the past 12 months.

What is Roivant Sciences Ltd.’s market cap?

Roivant Sciences Ltd.’s market cap is $11.10B.

When is Roivant Sciences Ltd.’s upcoming earnings report date?

Roivant Sciences Ltd.’s upcoming earnings report date is Nov 17, 2025 which is in 40 days.

How were Roivant Sciences Ltd.’s earnings last quarter?

Roivant Sciences Ltd. released its earnings results on Aug 11, 2025. The company reported -$0.252 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.002.

Is Roivant Sciences Ltd. overvalued?

According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences Ltd. pay dividends?

Roivant Sciences Ltd. does not currently pay dividends.

What is Roivant Sciences Ltd.’s EPS estimate?

Roivant Sciences Ltd.’s EPS estimate is -0.32.

How many shares outstanding does Roivant Sciences Ltd. have?

Roivant Sciences Ltd. has 682,881,700 shares outstanding.

What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?

Roivant Sciences Ltd. reported an EPS of -$0.252 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -2.785%.

Which hedge fund is a major shareholder of Roivant Sciences Ltd.?

Currently, no hedge funds are holding shares in ROIV

Roivant Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.84%

Trailing 12-Months

Asset Growth

-22.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Roivant Sciences Ltd.

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences (ROIV) Earnings & Revenues

Historic Earnings Reports

ROIV Company Deck

ROIV Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.View all ROIV earnings summaries

ROIV Stock 12 Month Forecast

Average Price Target

$20.31

▲(24.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","12.25":"$12.25","16.5":"$16.5","20.75":"$20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12.25,16.5,20.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,13.283076923076923,14.176153846153847,15.069230769230769,15.962307692307693,16.855384615384615,17.748461538461537,18.64153846153846,19.534615384615385,20.427692307692308,21.32076923076923,22.213846153846156,23.106923076923074,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.99923076923077,13.608461538461539,14.217692307692309,14.826923076923077,15.436153846153847,16.045384615384616,16.654615384615383,17.263846153846153,17.873076923076923,18.482307692307693,19.091538461538462,19.700769230769232,{"y":20.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.39,12.667692307692308,12.945384615384615,13.223076923076924,13.500769230769231,13.778461538461539,14.056153846153846,14.333846153846153,14.611538461538462,14.88923076923077,15.166923076923077,15.444615384615386,15.722307692307691,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >